Epidemiology and clinical relevance of microbial resistance determinants versus anti-Gram-positive agents

Current Opinion in Microbiology

Volumn 13, Issue 5, 2010, Pages 582-588

  Rossolini, Gian Maria ^a   Mantengoli, Elisabetta ^a   Montagnani, Francesca ^a   Pollini, Simona ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; CEFTAROLINE; CEFTOBIPROLE; CLINDAMYCIN; DALFOPRISTIN; DAPTOMYCIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; DNA TOPOISOMERASE IV; LINCOSAMIDE; LINEZOLID; MACROLIDE; OXAZOLIDINONE DERIVATIVE; PENICILLIN BINDING PROTEIN 2A; PENICILLIN BINDING PROTEIN 2X; PENICILLIN BINDING PROTEIN 5; PENICILLIN DERIVATIVE; PENICILLIN G; PENICILLINASE; PLEUROMUTILIN; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMYCIN; RIFAMYCIN DERIVATIVE; RNA POLYMERASE BETA SUBUNIT; TEICOPLANIN; TIGECYCLINE; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; BACTERIAL GENE; CLONE; CLOSTRIDIUM DIFFICILE INFECTION; EVOLUTION; GENE MUTATION; GENE TRANSFER; GRAM POSITIVE BACTERIUM; GRAM POSITIVE INFECTION; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NONHUMAN; PHENOTYPE; PROTEIN FUNCTION; REVIEW; STAPHYLOCOCCUS INFECTION;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROCOCCUS; EVOLUTION, MOLECULAR; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

CLOSTRIDIUM DIFFICILE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; POSIBACTERIA; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

EID: 77957783156     PISSN: 13695274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mib.2010.08.006     Document Type: Review

References (55)

1. Styers D., Sheehan D.J., Hogan P., Sahm D.F. Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States. Ann Clin Microbiol Antimicrob 2006, 5:2.
2. von Eiff C., Peters G., Heilmann C. Pathogenesis of infections due to coagulase-negative staphylococci. Lancet Infect Dis 2002, 2:677-685.
3. Chambers H.F., Deleo F.R. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol 2009, 7:629-641.
4. Fuda C., Suvorov M., Vakulenko S.B., Mobashery S. The basis for resistance to β-lactam antibiotics by penicillin-binding protein 2a of methicillin-resistant Staphylococcus aureus. J Biol Chem 2004, 279:40802-40806.
5. Grundmann H., Aires-de-Sousa M., Boyce J., Tiemersma E. Emergence and resurgence of methicillin-resistant Staphylococcus aureus as a public-health threat. Lancet 2006, 368:874-885.
6. Boucher H.W., Corey G.R. Epidemiology of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008, 46:S344-S349.
7. Classification of staphylococcal cassette chromosome mec (SCCmec): guidelines for reporting novel SCCmec elements. Antimicrob Agents Chemother 2009, 53:4961-4967. International Working Group on the Classification of Staphylococcal Cassette Chromosome Elements (IWG-SCC).
8. Tsubakishita S., Kuwahara-Arai K., Baba T., Hiramatsu K. Staphylococcal cassette chromosome mec-like element in Macrococcus caseolyticus. Antimicrob Agents Chemother 2010, 54:1469-1475.
9. Tsubakishita S, Kuwahara-Arai K, Sasaki T, Hiramatsu K: The reservoir and molecular evolution of the determinant of methicillin-resistance in staphylococci. Antimicrob Agents Chemother 2010, doi:10.1128/AAC.00356-10.
10. Enright M.C., Robinson D.A., Randle G., Feil E.J., Grundmann H., Spratt B.G. The evolutionary history of methicillin-resistant Staphylococcus aureus (MRSA). Proc Natl Acad Sci U S A 2002, 99:7687-7692.
11. DeLeo F.R., Chambers H.F. Reemergence of antibiotic-resistant Staphylococcus aureus in the genomics era. J Clin Invest 2009, 119:2464-2474.
12. Harris S.R., Feil E.J., Holden M.T., Quail M.A., Nickerson E.K., Chantratita N., Gardete S., Tavares A., Day N., Lindsay J.A., et al. Evolution of MRSA during hospital transmission and intercontinental spread. Science 2010, 327:469-474.
13. Deleo F.R., Otto M., Kreiswirth B.N., Chambers H.F. Community-associated methicillin-resistant Staphylococcus aureus. Lancet 2010, 375:1557-1568.
14. Chung M., Antignac A., Kim C., Tomasz A. Comparative study of the susceptibilities of major epidemic clones of methicillin-resistant Staphylococcus aureus to oxacillin and to the new broad-spectrum cephalosporin ceftobiprole. Antimicrob Agents Chemother 2008, 52:2709-2717.
15. Cornaglia G., Rossolini G.M. Forthcoming therapeutic perspectives for infections due to multidrug-resistant Gram-positive pathogens. Clin Microbiol Infect 2009, 15:218-223.
16. Livermore D.M., Mushtaq S., Warner M. Activity of the anti-MRSA carbapenem razupenem (PTZ601) against Enterobacteriaceae with defined resistance mechanisms. J Antimicrob Chemother 2009, 64:330-335.
17. Banerjee R., Gretes M., Basuino L., Strynadka N., Chambers H.F. In vitro selection and characterization of ceftobiprole-resistant methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2008, 52:2089-2096.
18. Howden B.P., Davies J.K., Johnson P.D., Stinear T.P., Grayson M.L. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev 2010, 23:99-139.
19. Sievert D.M., Rudrik J.T., Patel J.B., McDonald L.C., Wilkins M.J., Hageman J.C. Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. Clin Infect Dis 2008, 46:668-674.
20. Saha B., Singh A.K., Ghosh A., Bal M. Identification and characterization of a vancomycin-resistant Staphylococcus aureus isolated from Kolkata (South Asia). J Med Microbiol 2008, 57:72-79.
21. Aligholi M., Emaneini M., Jabalameli F., Shahsavan S., Dabiri H., Sedaght H. Emergence of high-level vancomycin-resistant Staphylococcus aureus in the Imam Khomeini Hospital in Tehran. Med Princ Pract 2008, 17:432-434.
22. Foucault M.L., Courvalin P., Grillot-Courvalin C. Fitness cost of VanA-type vancomycin resistance in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2009, 53:2354-2359.
23. Yang S.J., Nast C.C., Mishra N.N., Yeaman M.R., Fey P.D., Bayer A.S. Cell wall thickening is not a universal accompaniment of the daptomycin non-susceptibility phenotype in Staphylococcus aureus: evidence for multiple resistance mechanisms. Antimicrob Agents Chemother 2010, 54:3079-3085.
24. Besier S., Ludwig A., Zander J., Brade V., Wichelhaus T.A. Linezolid resistance in Staphylococcus aureus: gene dosage effect, stability, fitness costs, and cross-resistances. Antimicrob Agents Chemother 2008, 52:1570-1572.
25. Yang S.J., Kreiswirth B.N., Sakoulas G., Yeaman M.R., Xiong Y.Q., Sawa A., Bayer A.S. Enhanced expression of dltABCD is associated with the development of daptomycin nonsusceptibility in a clinical endocarditis isolate of Staphylococcus aureus. J Infect Dis 2009, 200:1916-1920.
26. Farrell D.J., Mendes R.E., Ross J.E., Jones R.N. Linezolid surveillance program results for 2008 (LEADER Program for 2008). Diagn Microbiol Infect Dis 2009, 65:392-403.
27. Long K.S., Poehlsgaard J., Kehrenberg C., Schwarz S., Vester B. The Cfr rRNA methyltransferase confers resistance to Phenicols, Lincosamides, Oxazolidinones, Pleuromutilins, and Streptogramin A antibiotics. Antimicrob Agents Chemother 2006, 50:2500-2505.
28. Morales G., Picazo J.J., Baos E., Candel F.J., Arribi A., Peláez B., Andrade R., de la Torre M.A., Fereres J., Sánchez-García M. Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus. Clin Infect Dis 2010, 50:821-825.
29. Sánchez García M., De la Torre M.A., Morales G., Peláez B., Tolón M.J., Domingo S., Candel F.J., Andrade R., Arribi A., García N., et al. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. JAMA 2010, 303:2260-2264.
30. Kehrenberg C., Schwarz S. Distribution of florfenicol resistance genes fexA and cfr among chloramphenicol-resistant Staphylococcus isolates. Antimicrob Agents Chemother 2006, 50:1156-1163.
31. Zapun A., Contreras-Martel C., Vernet T. Penicillin-binding proteins and β-lactam resistance. FEMS Microbiol Rev 2008, 32:361-385.
32. Hidron A.I., Edwards J.R., Patel J., Horan T.C., Sievert D.M., Pollock D.A., Fridkin S.K. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008, 29:996-1011. National Healthcare Safety Network Team and Participating National Healthcare Safety Network Facilities.
33. Murray B.E. β-Lactamase-producing enterococci. Antimicrob Agents Chemother 1992, 36:2355-2359.
34. Courvalin P. Vancomycin resistance in Gram-positive cocci. Clin Infect Dis 2006, 42:S25-S34.
35. Boyd D.A., Willey B.M., Fawcett D., Gillani N., Mulvey M.R. Molecular characterization of Enterococcus faecalis N06-0364 with low-level vancomycin resistance harboring a novel d-Ala-d-Ser gene cluster, vanL. Antimicrob Agents Chemother 2008, 52:2667-2672.
36. Willems R.J., Top J., van Santen M., Robinson D.A., Coque T.M., Baquero F., Grundmann H., Bonten M.J. Global spread of vancomycin-resistant Enterococcus faecium from distinct nosocomial genetic complex. Emerg Infect Dis 2005, 11:821-828.
37. Leavis H.L., Bonten M.J., Willems R.J. Identification of high-risk enterococcal clonal complexes: global dispersion and antibiotic resistance. Curr Opin Microbiol 2006, 9:454-460.
38. Efm colonization-virulence gene in megaplasmids of the Enterococcus faecium CC17 polyclonal subcluster. Antimicrob Agents Chemother 2010, 54:2660-2665.
39. Galloway-Peña J.R., Nallapareddy S.R., Arias C.A., Eliopoulos G.M., Murray B.E. Analysis of clonality and antibiotic resistance among early clinical isolates of Enterococcus faecium in the United States. J Infect Dis 2009, 200:1566-1573.
40. Efm-containing virulence plasmid in Enterococcus faecium. Antimicrob Agents Chemother 2009, 53:4240-4246.
41. Arias C.A., Murray B.E. Emergence and management of drug-resistant enterococcal infections. Expert Rev Anti Infect Ther 2008, 6:637-655.
42. Marshall S.H., Donskey C.J., Hutton-Thomas R., Salata R.A., Rice L.B. Gene dosage and linezolid resistance in Enterococcus faecium and Enterococcus faecalis. Antimicrob Agents Chemother 2002, 46:3334-3336.
43. Rahim S., Pillai S.K., Gold H.S., Venkataraman L., Inglima K., Press R.A. Linezolid-resistant, vancomycin-resistant Enterococcus faecium infection in patients without prior exposure to linezolid. Clin Infect Dis 2003, 36:146-148.
44. Schulte B., Heininger A., Autenrieth I.B., Wolz C. Emergence of increasing linezolid-resistance in enterococci in a post-outbreak situation with vancomycin-resistant Enterococcus faecium. Epidemiol Infect 2008, 136:1131-1133.
45. Liñares J., Ardanuy C., Pallares R., Fenoll A. Changes in antimicrobial resistance, serotypes, and genotypes in Streptococcus pneumoniae over a thirty-year period. Clin Microbiol Infect 2010, 16:402-410.
46. Darabi A., Hocquet D., Dowzicky M.J. Antimicrobial activity against Streptococcus pneumoniae and Haemophilus influenzae collected globally between 2004 and 2008 as part of the Tigecycline Evaluation and Surveillance Trial. Diagn Microbiol Infect Dis 2010, 67:78-86.
47. Chiu C.H., Su L.H., Huang Y.C., Lai J.C., Chen H.L., Wu T.L., Lin T.Y. Increasing ceftriaxone resistance and multiple alterations of penicillin-binding proteins among penicillin-resistant Streptococcus pneumoniae isolates in Taiwan. Antimicrob Agents Chemother 2007, 51:3404-3406.
48. Varaldo P.E., Montanari M.P., Giovanetti E. Genetic elements responsible for erythromycin resistance in streptococci. Antimicrob Agents Chemother 2009, 53:343-353.
49. Yokota S., Sato K., Kuwahara O., Habadera S., Tsukamoto N., Ohuchi H., Akizawa H., Himi T., Fujii N. Fluoroquinolone-resistant Streptococcus pneumoniae strains occur frequently in elderly patients in Japan. Antimicrob Agents Chemother 2002, 46:3311-3315.
50. Adam H.J., Hoban D.J., Gin A.S., Zhanel G.G. Association between fluoroquinolone usage and a dramatic rise in ciprofloxacin-resistant Streptococcus pneumoniae in Canada, 1997-2006. Int J Antimicrob Agents 2009, 34:82-85.
51. Huang H., Weintraub A., Fang H., Nord C.E. Antimicrobial resistance in Clostridium difficile. Int J Antimicrob Agents 2009, 34:516-522.
52. Shah D., Dang M.-D., Hasburn R., Koo H.L., Jiang Z.-D., DuPont H.L., Garey K.W. Clostridium difficile infection: update on emerging antibiotic options and antibiotic resistance. Expert Rev Anti Infect Ther 2010, 8:555-564.
53. Curry S.R., March J.W., Shutt K.A., Muto C.A., O'Leary M.M., Saul M.I., Pasculle A.W., Harrison L.H. High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital. Clin Infect Dis 2009, 48:425-429.
54. Clements A.C.A., Soares Magalhaes R.J., Tatem A.J., Paterson D.L., Riley T.V. Clostridium difficile PCR ribotype 027: assessing the risks of further worldwide spread. Lancet Infect Dis 2010, 10:395-404.
55. Coia J.E. What is the role of antimicrobial resistance in the new epidemic of Clostridium difficile?. Int J Antimicrob Agents 2009, 33(S1):S9-S12.